UNSPSC 51263120: Cloranolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H19Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3U058H86V, chemically known as 2-propanol, 1-(2,5-dichlorophenoxy)-3-((1,1-dimethylethyl)amino)- but generally known as cloranolol, which bears US NIH Compound Identifier 65814. European Medicines Agency schedules Cloranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06752MIG.

UNSPSC 51263120 Cloranolol is a Commodity code that captures pharmaceutical products and related health-service consumables procured by state and local health agencies. Recent state and local opportunities under this code show activity in opioid-response medications and pharmacy benefit management systems rather than cloranolol itself — specifically, naloxone procurement and direct-to-manufacturer prescription program implementation. State health and human services agencies and county health departments are the primary issuing bodies, with Seminole County, Florida and the Texas Health and Human Services Commission driving recent solicitations. The work involves acquiring finished pharmaceutical products for community health distribution, implementing pharmacy benefit structures that bypass traditional pharmacy benefit managers and group purchasing organizations, and managing quarterly or ongoing pharmaceutical supply chains with compliance requirements including E-Verify, drug-free workplace certification, and federal environmental and safety regulations.

Recent activity centers in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida and a response deadline of July 26, 2023; the contract includes a two-year initial term with one-year renewal option and potential FEMA funding. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore vendor capabilities for direct-to-manufacturer prescription programs that would allow self-insured state employee health plans and government agencies to contract directly with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels, with responses due April 3, 2026. Neither solicitation specifies set-aside or disadvantaged-enterprise preferences.